Celcuity (CELC) stock: gedatolisib Phase 3 VIKTORIA-1 PFS gains in HR+/HER2- breast cancer, runway to 2027 and valuation ...
Gedatolisib, Faslodex, and Ibrance combination significantly improved progression-free survival in advanced breast cancer patients, reducing disease progression risk by 76%. The triplet regimen ...
(Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced updates to the Phase 3 ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
(RTTNews) - Shares of Celcuity Inc. (CELC) touched an all-time high of $53.85 in early trading today, building on several eventful months driven by developments surrounding its lead drug candidate, ...
On Thursday, Celcuity Inc. CELC announced amendments to its Phase 3 VIKTORIA-2 clinical trial evaluating gedatolisib as a ...
Celcuity (CELC) announced overall survival, OS, data from two patient cohorts evaluated in a Phase 1b trial with gedatolisib, a pan-PI3K/mTORC1/2 inhibitor, in combination with palbociclib and either ...
The company expects top line data from the PIK3CA mutant cohort of the VIKTORIA-1 trial in late Q1 or Q2 2026. Sullivan stated, "We expect to complete the submission [to FDA] this quarter." The ...
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study This phase III randomized trial (VIKTORIA-1; ...
BERLIN — The investigational drug gedatolisib substantially extends progression-free survival (PFS) among patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer that has ...
Celcuity ( (CELC)) just unveiled an announcement. On May 1, 2026, Celcuity announced positive topline Phase 3 VIKTORIA-1 results in patients with PIK3CA mutant HR+/HER2- advanced or metastatic breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results